semaglutide nash phase 3 Exciting Data from Novo Nordisk for Patients with MASH Semaglutide in MASH with F2-F3

Growing research suggests prolonged GLP-1 use may be linked to bone density changes

Ewa Timek provides patients with Semaglutide to help them lose weight using proven medication.

Methods A short-term cost-effectiveness analysis was conducted from the perspective of the Greek third-party payer [National Organization for the Provision of Health Services (EOPYY)], comparing costs and outcomes for semaglutide 2.4 mg and liraglutide 3 mg over a 68-week horizon

Clinician-guided GLP-1 program for IVF or pregnancy

There are currently two major players with a decisive head start in the obesity drug space: Eli Lilly (LLY) and Novo Nordisk (NVO)